Beware of the swinging pendulum: anti-tumor necrosis factor monotherapy vs combination therapy for inflammatory bowel disease

Gastroenterology. 2014 Apr;146(4):884-7. doi: 10.1053/j.gastro.2014.02.018. Epub 2014 Feb 25.
No abstract available

Publication types

  • Editorial
  • Research Support, U.S. Gov't, P.H.S.
  • Comment

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Crohn Disease / drug therapy*
  • Female
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Immunologic Factors / adverse effects*
  • Male
  • Neoplasms / chemically induced*

Substances

  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • Immunologic Factors
  • Adalimumab